Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an update.
Lumos Diagnostics has secured additional U.S. Medicare reimbursement coverage for its FebriDx® test from two more Medicare Administrative Contractors (MACs), First Coast Service Options and Noridian Healthcare Solutions. This achievement expands Lumos’ Medicare coverage to four out of seven MACs, covering over 55% of U.S. Medicare payments. This milestone is crucial for the commercial success of FebriDx, as Medicare adoption often influences private insurance payors’ decisions. Lumos continues to pursue coverage from the remaining MACs and private payors to achieve nationwide access and support broad clinical adoption.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing diagnostic solutions that improve patient care, integrate into care pathways, and deliver value to the healthcare system.
YTD Price Performance: -37.50%
Average Trading Volume: 1,360,987
Technical Sentiment Signal: Buy
Current Market Cap: A$18.71M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.